Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...
The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...
The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.
4d
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a ...
As the exam dates are nearing, the anticipation and anxiety to complete the syllabus are high among students. So many ...
Precise Bio, a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with an initial focus on ophthalmology, has successfully treated the first patient with PB-001, ...
Orthopedic Research Center, Department of Orthopedic Surgery, Mashhad University of Medical Science, Mashhad 91779-48564, Iran Bone and Joint Research Laboratory, Ghaem Hospital, Mashhad University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback